Company intelligence / Profile preview

Jeune Aesthetics

Pittsburgh, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Jeune Aesthetics has reported positive Phase 1 results for multiple programs. KB301 showed meaningful and sustained improvements in lateral canthal lines and décolleté wrinkles with positive durability results. KB304 demonstrated significant aesthetic improvements with 100% of treated subjects reporting improvements at three months in wrinkles, elasticity, and hydration. The company is advancing KB301 to Phase 2 and plans to initiate Phase 2 for KB304 in the first half of 2026.

Therapeutic areas: Dermatology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

4 assets

KB301

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Jeune Aesthetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jeune Aesthetics.

Explore the full profile